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S_q Treatment and survival rates of patients with non-small-cell lung cancer (NSCLC) were compared
between three French Cancer Regisries (Calvados, Doubs, Tarn). The methodological issues in such com-
parisons are discunsed- The treatments for NSCLC differed betwen the regions: radiotherapy tended to be
preferred in Calvados (73% vs 21.3% surgery), whereas surgery was more firquently employed in Doubs and
Tarn (27.7% and 37% respectivdy). The percentage of cases ving no therapeutic treatment ranged from
7.8% (Calados) to 26% (Tarn). Despite the differences in treatment, the overall swrival rates were similar in
the three regons Adjustment for tratment m snch a desrpte study may be misleing since different
therapeutic strategies in different regions may kad to seection of patients of systematically better or poorer
prognosis in the various treatment groups.
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Lung (bronchus) cancer ranks first for both mortality and
morbidity in men in Frnce (Hill et at., 1989; Benhamou et
al., 1990). Although its incidence is low in women, it is
increasing, and is hikely to continue to do so in view of the
increasing numbers offemale smokers. The prognosis for this
cancer is still extrmely poor and progress in suitable
therapies is slow. Although there is a lack of consensus on
the treatment of primary bronchial cancer, crrtain ruls are
widely accepted. It is gneraly considered that 25-30% of
non-small-cel lung cancer (NSCLC) can be treated by
surgery, and that radiotherapy is beneficial in 30% of other
cases with more advanced stages (Johnson et al., 1990).
Pallative thoracic radiotherapy is also employed to reduce
the major symptoms caused by tumoral extension (MRC
Lung Cancer Working Party, 1991). A survival benefit of
chemotherapy has been demonstrated in a randomised trial
(Rapp et al., 1988), although the adverse effects of
chemotherapy have tnded to restrict its use in this applica-
tion (Splinter, 1990). Practitioners still lack effective treat-
ment for a large number oflung tumours, which accounts for
the diversity of strategies and the decision to withhold
therapeutic treatment in numerous cases.
Although hospital sries have indicated an increase in
therapeutic efficacy, this was not confirmed in a recent study
from the Scottish Cancer Registry, which failed to observe
any overall improvement in the prognosis oflung cancer over
the last 25 years (Black et al., 1993). The therapeutic progress
observed in hospital series may be attributed to the selection
of the patients who are given the potentially more efficacious
therapy. Population-based data are therefore of particular
interest, although they do pose problems ofcomparability. In
the present study we analysed data from three population-
based cancer registries in an attempt to discern differences in
treatment and overall survival from lung ancer in three
disti regions of France.
Materaas m o
Out of the five general population-based ancer mgistries in
France, three, Calvados in the north-west, Doubs in the east
and Tarn in the south, possessed data relevant to this study.
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These regions also differ in their accessibility to health care.
These three regisries made available to us all cases of
primary NSCLC diagnosed during the period 1987-88 for
Doubs and Tarn, and in 1987 for Calvados. The present
study included 615 cases (141 in Calvados, 274 in Doubs and
200 in Tarn). Age, gender histological type of tumour and
treatment were recorded, but extent of disease or staging
were not available. None of these three registries use autopsy
reports as a data source. Under French legislation the death
certificate cannot be employed as a data source, so there are
no cases registed by death certificate only (DCO) in our
study. The status (alive/dead) of all cases was ascertained on
31 December 1989. The information was collcted by post
from the department of vital statistics at the patient's place
of birth. If the place of birth was not known, the patient's
own doctor was contacted for the relevant information.
Status data were obtained for 98% of the cases.
The age at diagnosis was known for all patients, and was
split into three age ranges (<55 years, 55-74 years, >75
years) for the statistical analysis. A total of 97.8% of the
cases had benefited from a pathological or cytological
examination, and the result was coded according to the
ICD-O clasification (WHO, 1976). For the purpose of
analysis, the tumours were grouped into four large
categories: epidermoid carcinoma (ICD-0 codes 80703,
80713, 80723, 80733), adenocarcinoma (ICD-O codes 81403,
81903, 82003, 82113, 82503, 82603, 83103, 84813), other
documented pathological types (ICD-O codes 80123, 80203,
80213, 80313, 82403, 85603) and a fourth category including
imprecse (ICD-O codes 80003, 80013, 80103) and absence of
pathological/cytological examination. The treatment was
coded in terms of three binary variables: surgery, radio-
therapy and chemotherapy; rdical and palliative treatment
were not distinguished. The treatments received were known
and were verified in each case, apart from two patients for
whom the chemotherapy data were unavailable.
The distributions of tumour type, gender and age in the
different regions were analysed using the chi-square test. The
proportions of treated patients by age, gender, tumour mor-
phology and regions were analysed by logistic regression.
Survival univariate analysis was made using actuarial
methods. The Cox model was employed for the multivariate
survival analysis and the assumption ofproportional hazards
was checked graphically. The analyses were carried out using
BMDP statistical software (F4, LR, IL, 2L; Dixon, 1992).Results
General characteristics (Table IJ
Differences in age distribution were noted between the three
regions with younger cases in Calvados and older ones in
Tarn. This was only partly due to the age structure of the
population in the region, as for the period 1982-87 (Parkin
et al.. 1992) the incidence rate in young patients was higher
in Calvados and Doubs than in Tarn. There was also a
different sex distnrbution. Females represented 13.9% of the
cases in Doubs compared with 8.5% in Calvados and 6% in
Tarn (P<0.05), although this only partially accounts for the
differences observed in the distribution of the histological
types. Doubs was charactenised by an overrepresentation of
adenocarcinoma. Epidermoid cancer was more frequent in
Tarn. The difference in pathological type between the regions
(P> 0.01) was still observed after adjustment for age
(P>0.01) and sex (P>0.01).
Treatment (Table 11)
Overall radiotherapy is used in 50.90o of the patients,
chemotherapy in 30.3% and surgery in 29.3%. A total of
22.4% of the patients were treated by a combination of two
treatments and 300 by a combination of three treatments;
18.2% received no therapeutic treatment. These figures
however mask considerable differences between regions. In
Calvados 73% of the cases received radiotherapy (as sole
treatment in two out of three cases). whereas less than half of
the cases in the other two regions benefited from radio-
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therapy. Surgery was more frequently employed in Tarn
(37%) than in Doubs (27.7%) or Calvados (21.3%).
Chemotherapy was used most in the Doubs region (39.1% of
the cases), and the proportion of cases receiving no
therapeutic treatment ranged from 7.8% in Calvados to 26%
in Tarn. The percentage of cases not receiving therapeutic
treatment was higher for those lacking accurate pathological
data. This percentage also was found to increase with age.
Marked interregional differences emerged on analysis of
the therapeutic treatments by logistic regression, even after
taking the effects of age, gender and morphology into
account (Table III). The results were in agreement with those
of the univariate analysis. Surgery was more frequently
employed in Tarn than in the other regions. Therapeutic
treatment was also withheld more frequently in the Tarn
region. Radiotherapy was more often used in Calvados, while
chemotherapy was more frequently employed in Doubs than
in the other two regions.
Survival
A univariate analysis of survival 18 months after diagnosis
(Table IV) did not show any significant difference between
regions (29.8% in Calvados, 30.0% in Tarn, 34.8% in
Doubs) even after the effects of age or gender were taken
into account. However, age and surgical treatment were cor-
related with prognosis. There was no difference in survival
rates between the morphological groups, except for the cases
with imprecise pathological results who had a lower survival
rate. In view of the regional disparity in different variables
(age, sex and pathological type), a multivariate analysis using
Table I General charactenrstics in each region
Calvados (O% Daubs (%) Tarn ( Total (O%
Age (years)
<55 25 (17.7) 51 (18.6) 19 (9.5) 95 (15.4)
55 -74 97 (68.8) 164 (59.9) 131 (65.5) 392 (63.7)
> 75 19 (13.5) 59 (21.3) 50 (25.0) 128 (20.8)
Sex
Male 129 (91.5) 236 (86.1) 188 (94.0) 553 (89.9)
Female 12 (8.5) 38 (13.9) 12 (6.0) 62 (10.1)
Morphology
Epidermoid 78 (55.3) 175 (63.9) 140 (70.0) 393 (63.9)
Adenocarcinoma 25 (17.7) 74 (27.0) 39 (19.5) 138 (22.4)
Other 22 (15.6) 2 (0.7) 8 (4.0) 32 (5.2)
NOS carcinoma 16 (11.3) 23 (8.4) 13 (6.5) 52 (8.5)
Total 141 274 200 615
Table n Treatment according to age, sex, morphology and region
Surgery Radiotherapy Chemotherapy No treatment
(%/) (%) (%/) (%/)
Age (years)
< 55 35 (36.8) 54 (56.8) 42 (44.2) 6 (6.3)
55-74 136 (34.7) 201 (51.2) 126 (32.1) 57 (14.5)
) 75 9 (7.0) 58 (45.8) 18 (14.1) 49 (38.3)
Sex
Male 157 (28.4) 282 (50.1) 163 (29.3) 103 (18.5)
Female 23 (37.1) 31 (50.0) 23 (37.1) 9 (14.5)
Morphology
Epidermoid 118 (30.0) 208 (52.9) 114 (29.0) 67 (17.0)
Adenocarcinoma 50 (36.2) 66 (47.8) 44 (31.9) 24 (17.4)
Other 7 (21.9) 16 (50.0) 12 (37.5) 5 (15.6)
NOS carcinoma 5 (9.6) 23 (44.2) 16 (30.8) 16 (30.8)
Region
Calvados 30 (21.3) 103 (73.0) 27 (19.3) 11 (7.8)
Doubs 76 (27.7) 131 (47.8) 107 (39.1) 49 (17.9)
Tarn 74 (37.0) 79 (39.5) 52 (26.0) 52 (26.0)
Total 180 313 186 112
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Table m Multivariate analysis: differences in the treatment between age, sex, morphology and region
Surgery Radiotherapy Chemotherap) No treatment
Standard Standard Standard Standard
ORa error P-valueb OR' error P-valueb ORa error P-valueb ORO error P-valueb
Age (years)
<55 1.20 0.247 NS 1.23 0.240 NS 1.60 0.241 NS 0.41 0.450 P<0.05 55-74C 1.00 1.00 1.00 1.00
> 75 0.13 0.366 P<0.001 0.88 0.214 NS 0.31 0.283 P<0.001 3.36 0.237 P<0.001
Sex
Male 0.72 0.305 NS 1.00 0.288 NS 0.83 0.303 NS 1.26 0.410 NS
Femalec 1.00 1.00 1.00 1.00
Morphology
Epidermoid' 1.00 1.00 1.00 1.00
Adenocarcinoma 1.25 0.226 NS 0.79 0.211 NS 0.98 0.230 NS 1.21 0.282 NS
Other 0.63 0.468 NS 0.43 0.414 P<0.05 2.21 0.419 NS 1.88 0.564 NS
NOS carcinoma 0.32 0.495 P<0.05 0.58 0.317 NS 1.36 0.342 NS 2.21 0.364 P<0.05
Region
Calvados 0.41 0.305 P<0.001 4.66 0.252 P<0.001 0.49 0.288 P<0.05 0.25 0.370 P<0.001
Doubs 0.56 0.270 P<0.01 1.38 0.193 NS 1.74 0.212 P<0.01 0.66 0.240 NS
Tarn' 1.00 1.00 1.00 1.00
'Odds ratios for the treatment probabilities incategories compared with the reference category. bPValue for cofficients standard error. 'Referce
category. NS, not significant, P> 0.05.
the Cox model was camred out. No difference in survival
between regions was found after adjustment (Table V). Age
remained a significant risk factor, and significantly lower
survivals were observed for the adenocarcinomas and for the
cases with imprecise pathological results than for the other
morphological types.
This analysis was carried out under the auspices of Eurocare,
a concerned association of European population-based
cancer registries (Berrino et al., 1995). Its objective is to
obtain information on the treatment and survivaL rates of all
patients with lung cancer in the population. This study thus
avoids the selection bias deriving from use of hospital series,
and was designed to provide baseline information for assess-
ment of the overall treatment ofcancer patients by the health
system. The data were obtained from complementary inform-
ation on all the cases recorded by the relevant cancer
registries over a given period. Various outside sources of
information were consulted for each case to make the study
Table IV Survival of non-small-cell lung cancer (95% confidence
intervals in parentheses)
Survival at 18 months
(%0) Log ran*k P-value
Sex
Male 31.7 (27.7-35.9) N Female 34.0 (23.0-47.0) 0.096 NS
Age (years)
< 55 40.1 (30.3-50.7)








Adenocarcinoma 31.7 (24.1-40.3) 12.8 P<0.01
Other 37.5 (22.9-54.7)
NOS carcinoma 18.3 (10.0-31.3)
Treatment
Surgery 65.8 (58.1 -72.8)
Other 18.6 (14.1-23.6) 139.6 P<0.001
No treatment 16.1 (10.3-24.3)
NS, not significant, P> 0.05.
as exhaustive as possible. In an attempt to obtain high
quality data, we deliberately omitted data on the clinical
stage of the tumour, and only collected information pertain-
ing to treatment. Reliable data on the clinical stage are often
not available, and the relatively high proportion of hospital
records with no mention of the clinical stage has also been
noted in a recent English study (Gulliford et al., 1993). An
American study showed that this absence was even more
frequent for lung cancer than for other cancers, such as those
of breast or colon (Feigl et al., 1988). Although this does
have some influence on the interpretation of our results, we
thought it unlikely that there would be large differences in
the distribution of the clinical stages at the time of diagnosis
between the three regions.
The observed distribution of pathological types is consis-
tent with that seen in other populations. Among lung
cancers, the proportion of squamous cell carcinoma ranges
from 45% to 50% and that of adenocarcinoma from 16% to
25% in the different European registries (Lutz et al., 1988;
Registre Genevois des Tumeurs, 1989; Zanetti et al., 1992).
The variations in the proportions of adenocarcinomas can be
explained by the inclusion in the lung cancer category of
different proportions of cases with primary or doubtful
secondary tumours.
Table V Factors associated with survival at 18 months of
non-small-cell lung cancer: multivanrate analysis
Hazard ratioa Standard error P-valueb
Age (years)
<55 0.71 0.146 P<0.01
55-74c 1.00
) 75 1.58 0.118 P<0.01
Sex




Adenocarcinoma 1.28 0.124 P<0.05
Other 0.92 0.216 NS
NOS carcinoma 1.6 0.164 P<0.01
Region
Calvados 1.13 0.128 NS
Doubs 0.98 0.114 NS
Tarnc 1.00
'Hazard ratios in categories compared with the reference category.
'P-value for coefficients/standard error. cReference category. NS, not
significant, P>0.05.T _ S #Fot n m r d NSCLC i Frm
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There was a marked regional difference in trtment,
which also emerged from a previous study on diagnostic
attitude and regular treatment of lung cancer in 70 hospital
teams (Mazover et al., 1989). In our study, the differences in
therapies between regons cannot be accounted for by
differences in age, gender and morphology. The largest
differences in treatment were observed between Calvados and
Tarn, with Doubs being in the intermediate position.
Radiotherapy was frequently employed in Calvados, often as
sole treatment and in relatively few cases in combination with
surgery. This contrasted with the situation in Tarn, where
NSCLCs were generally treated surgically. The difference in
therapeutic strategy has an influence on the number of non-
treated patients. The fact that radiotherapy has fewer con-
traindications than surgery means that it can be employed on
a larger proportion of patients, especially the eklerly, and
may account for the smaler proportion of untreated patients
in Calvados compared with Tarn. The regional differences in
treatment strategies may be explained by differences in the
availability of services. For example, Calvados has a com-
prehensive cancer centre where radiotherapy is one of its
specialties, whereas in Tarn many patients are treated in
private clinics lacing specialised services.
There have been few detailed stui on lung cancer sur-
vival based on population data (Watkin et al., 1990; Sant et
al., 1992). Most of the data on pathological types and
treatments come from hospital data and the results of
therapeutic trials, which are not readily extrapolated to the
whole population of patients in a given region.
A more favourable prognosis for women has been noted
by some cancer registries (Registre Genevois des Tumeurs,
1989; National Cancer Institute, 1991), although this has not
been reported by other authors (McDuffie et al., 1991; Sant
et al., 1992). To our knowledge, the poor prognosis of
adenocarcinoma found in the present study has not been
reported before. This illustrates the lack of comparability
between the survival results of clinical trials and those
obtained from population-based cancer registry data. The
patients participating in clinical trials usually have complete
records indicating the primary nature of the tumour, whereas
the cancer registry data may include a number of secondary
adenocarcinomas. These cancers, which are already meta-
static, do not have a good prognosis and thus reduce the
mean survival rate of the whole group.
The higher mortality of the older patients observed in our
study is in line with the results of the study of the SEER
Program comparing the relative survival of patients of
different ages at the same clinical stage (Kant et al., 1992).
Despite the differences in treatment, espeialy in the use of
surgery, there was no overall difference in survival rates
between the three regions. The prognostic value of surgery
differed from one region to another, and its effectiveness
appeared to be higher in the regions where it was least used.
The greater use of surgery in Tarn is explained by the choice
of surgical treatment for patients with an a priori poor
prognosis. The prognosis for both surgically and non-
surgically treated patients was thus worse in Tarn than in
Calvados (Figure 1). For this reason, the introduction of this
variable (surgery vs no surgery) in the model may be
miskading (Table VI, models 1 and 2), since the assignment
of patients to treatments did not imply the same a priori
prognosis in the different region. The adjustment for surgery
would therefore suggest that survival is signiicntly better in
Doubs and in Calvados than in Tarn where a priori prog-
nosis is worse than the two other populations, both for
surgically treated patients and non-surgicaly treated patients.
This phenomenon is similar to that described by Feinstein for
stage migration, and has been referred to as the Will Rogers
Phenomenon (Feinstein et al., 1985). Treatment-adjusted
analysis can erroneously predict a higher survival in areas (or
groups) where the indications are the most selective, whereas
the results for the overall population are identical in both
areas.
Coecmo.
This study confirms the poor prognosis of lung cancer and
the marked difference between patients who benefit from
surgery and those who do not. We found a considerable
diversity in the treatments offered between regions, and
differences in the percentage ofcases receiving no therapeutic
treatment. These differences had no influence on survival
rate, however, which was similar in the three regions. These













Figwe 1 Survival of non-small-cell lung cancer in relation to
treatment. Sugery: 0, Calvados; 0, Tarn; A Doubs. No
surgery: A, Doubs; *, Calvados; 0, Tarn.
Table VI Multivariate analysis, adjustment on treatment
Model I Model 2
Hazard ratio' Standard error P-vh' Hazardratio' Standarderror P-vahueb
Age (years)
<55 0.71 0.146 P<0.01 0.81 0.146 NS
55-74' 1.00 1.00
> 75 1.58 0.118 P<0.01 1.06 0.119 NS
Region
Calvados 1.13 0.128 NS 0.83 0.130 NS
Doubs 0.98 0.114 NS 0.73 0.116 P<0.01
Tarn' 1.00 1.00
Treatment
Surgery 0.21 0.139 P<0.001
No surgery' 1.00
Analysis adjusted on sex and morphology. 'Hazard rat incategories compared with the reference category. bP-value forcoefficients/standard error. cReference category. NS, not signficant, P>0.05.
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differences between hospital series can be accounted for in
terms of differences in the selection of patients. This high-
lights the utility of population data for an exact representa-
tion of lung cancer treatments, but also shows the inherent
limitations of our data. To interpret the data in more detail
and identify selection effects, registries need to record more
comprehensive data, especially the clinical stage of the
tumour at diagnosis. This will in turn require a closer col-
laboration with the relevant clinicians as this information is
often not included in the hospital records.
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